10x Genomics, Inc. (FRA:1KJ)

10x Genomics Statistics

Total Valuation

10x Genomics has a market cap or net worth of EUR 2.05 billion. The enterprise value is 1.67 billion.

Market Cap	2.05B
Enterprise Value	1.67B

Important Dates

The last earnings date was Thursday, February 12, 2026.

Earnings Date	Feb 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	117.67M
Shares Outstanding	n/a
Shares Change (YoY)	+3.57%
Shares Change (QoQ)	+1.26%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	115.51M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.74
PB Ratio	3.02
P/TBV Ratio	3.30
P/FCF Ratio	18.47
P/OCF Ratio	17.67
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-45.15
EV / Sales	3.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	15.11

Financial Position

The company has a current ratio of 4.46, with a Debt / Equity ratio of 0.11.

Current Ratio	4.46
Quick Ratio	3.95
Debt / Equity	0.11
Debt / EBITDA	n/a
Debt / FCF	0.65
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -5.78% and return on invested capital (ROIC) is -7.49%.

Return on Equity (ROE)	-5.78%
Return on Assets (ROA)	-6.40%
Return on Invested Capital (ROIC)	-7.49%
Return on Capital Employed (ROCE)	-11.29%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	464,764
Profits Per Employee	-31,483
Employee Count	1,178
Asset Turnover	0.66
Inventory Turnover	2.85

Taxes

In the past 12 months, 10x Genomics has paid 3.10 million in taxes.

Income Tax	3.10M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +41.80% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+41.80%
50-Day Moving Average	15.92
200-Day Moving Average	12.14
Relative Strength Index (RSI)	49.69
Average Volume (20 Days)	30

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.38

Income Statement

In the last 12 months, 10x Genomics had revenue of EUR 547.49 million and -37.09 million in losses. Loss per share was -0.30.

Revenue	547.49M
Gross Profit	378.48M
Operating Income	-85.41M
Pretax Income	-33.99M
Net Income	-37.09M
EBITDA	-54.58M
EBIT	-85.41M
Loss Per Share	-0.30

Balance Sheet

The company has 445.79 million in cash and 71.85 million in debt, with a net cash position of 373.94 million.

Cash & Cash Equivalents	445.79M
Total Debt	71.85M
Net Cash	373.94M
Net Cash Per Share	n/a
Equity (Book Value)	678.23M
Book Value Per Share	5.31
Working Capital	452.25M

Cash Flow

In the last 12 months, operating cash flow was 115.87 million and capital expenditures -5.05 million, giving a free cash flow of 110.82 million.

Operating Cash Flow	115.87M
Capital Expenditures	-5.05M
Free Cash Flow	110.82M
FCF Per Share	n/a

Margins

Gross margin is 69.13%, with operating and profit margins of -15.60% and -6.77%.

Gross Margin	69.13%
Operating Margin	-15.60%
Pretax Margin	-6.21%
Profit Margin	-6.77%
EBITDA Margin	-9.97%
EBIT Margin	-15.60%
FCF Margin	20.24%

Dividends & Yields

10x Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.57%
Shareholder Yield	-3.57%
Earnings Yield	-1.81%
FCF Yield	5.41%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

10x Genomics has an Altman Z-Score of 2.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.67
Piotroski F-Score	4